Exact Sciences (EXAS) Tops Q3 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Exact Sciences Announces Third Quarter 2022 Results
November 3, 2022 4:05 PM EDTReports Record Revenue, Raises Full-Year Guidance, Accelerates Path to Profitability
Third quarter highlights
Total third quarter revenue, excluding COVID-19 testing, increased 20 percent compared to the third quarter of 2021, with Screening revenue of $361 million and Precision Oncology revenue of $151 millionFull-year revenue guidance raised by $33 million and operating expense guidance lowered by $113 million at the midpointsAdjusted EBITDA profitability now expected in the third quarter of 2023, ahead of previous target of 2024MADISON, Wis., Nov. 3, 2022 /PRNewswire/... More
